FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... August 3, 2020 Latest episode of our podcast for researchers May 23, 2022 Caregivers Empower the Next Generation of Cancer Care August 3, 2023 Remembering With Gratitude January 7, 2021 Load more HOT NEWS Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20... Why it’s difficult to estimate the number of extra cancer deaths... 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients...
